# US 2019/0169191 A1 · Substituted purine derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169191 A1
- Document ID: US20190169191A1
- Status: Published application
- Kind: A1
- Application number: 16/095,822
- Filed: 2017-04-25
- Published: 2019-06-06
- Earliest claimed: 2016-04-26
- Assignees: Sumitomo Dainippon Pharma Co., Ltd.
- Applicants: Sumitomo Dainippon Pharma Co., Ltd.
- Inventors: Shingo TOJO; Yoshiaki ISOBE; Eiji IDEUE; Hiroaki FUJIWARA; Daisuke URABE
- Web page: https://patentgrep.com/patent/US20190169191A1

## CPC

- C07D 473/18: one oxygen and one nitrogen atom, e.g. guanine
- A61K 31/52: Purines, e.g. adenine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07D 473/16: two nitrogen atoms
- C07D 473/28: Oxygen atom
- C07D 473/34: attached in position 6, e.g. adenine
- C07D 473/40: with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a substituted purine derivative of formula (1) wherein R1 is alkoxy or the like, R2 is alkyl or the like, Ring Q1 is aryl or the like, W1 is alkylene or the like, Ring Q2 is aromatic carbocyclyl or the like, n is 1-4, R3 is hydrogen atom or the like, X1 is single bond or the like, W2 is alkylene or the like, and R4 is hydrogen atom or the like, or a pharmaceutically acceptable salt thereof, which has a potent inhibitory effect against TLR7, and thereby is useful for treating autoimmune disease.

## Claims

### Claim 1

A compound of formula (1):
or a pharmaceutically acceptable salt thereof
wherein
R1 is optionally-substituted C1-6 alkoxy, optionally-substituted C3-7 cycloalkoxy, optionally-substituted 4- to 10-membered saturated heterocyclyloxy, optionally-substituted C1-6 alkyl, optionally-substituted C3-7 cycloalkyl, optionally-substituted C1-6 alkylthio, optionally-substituted 4- to 10-membered saturated heterocyclyl, optionally-substituted amino, halogen atom, or hydroxy;
R2 is optionally-substituted C1-6 alkyl, optionally-substituted C3-7 cycloalkyl, or optionally-substituted amino;
Ring Q1 is optionally-substituted C6-10 aryl, or optionally-substituted 5- to 10-membered heteroaryl;
W1 is single bond, or optionally-substituted C1-4 alkylene;
Ring Q2 is C6-10 aromatic carbocyclyl, or 5- to 10-membered aromatic heterocyclyl;
n is 1, 2, 3, or 4;
R3 is, independently if there are plural R3, hydrogen atom, halogen atom, cyano, hydroxy, optionally-substituted C1-6 alkyl, optionally-substituted C1-6 alkoxy, optionally-substituted C3-7 cycloalkyl, optionally-substituted C3-7 cycloalkoxy, or optionally-substituted amino;
Q2-X1— is Q2-(single bond)-, Q2-(CH2)m—O—, Q2-(CH2)m—S—, Q2-(CH2)m—S(O)2—, Q2-(CH2)m—NRaS(O)2—, Q2-(CH2)m—S(O)2NRa—, Q2-(CH2)m—C(O)—, Q2-(CH2)m—NRa—, Q2-(CH2)m—NRaC(O)—, or Q2-(CH2)m—C(O)NRa—, wherein Ra is hydrogen atom or C1-6 alkyl; m is 0, 1, or 2;
W2 is single bond, or optionally-substituted C1-8 alkylene; and
R4 is hydrogen atom, —ORb (wherein Rb is hydrogen atom, optionally-substituted C1-6 alkyl, optionally-substituted C1-6 alkylcarbonyl, optionally-substituted aminocarbonyl, or optionally-substituted C1-6 alkylsulfonyl), —NRcRd (wherein Rc is hydrogen atom or optionally-substituted C1-6 alkyl; and Rd is hydrogen atom, optionally-substituted C1-6 alkyl, optionally-substituted C1-6 alkylcarbonyl, optionally-substituted C1-6 alkoxycarbonyl, or optionally-substituted C1-6 alkylsulfonyl), optionally-substituted 4- to 10-membered saturated heterocyclyl, or optionally-substituted 5- to 10-membered heteroaryl.

### Claim 2 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
R1 is
(1) C1-6 alkoxy which may be substituted with 1-3 the same or different substituents selected from the group consisting of
(a) halogen atom,
(b) hydroxy,
(c) C1-6 alkoxy which may be substituted with 1-3 the same or different halogen atoms,
(d) C3-7 cycloalkyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy,
(e) C3-7 cycloalkoxy which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy,
(f) phenyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy,
(g) 5- or 6-membered heteroaryl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy, and
(h) 4- to 7-membered saturated heterocyclyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy,
(2) C3-7 cycloalkoxy which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy,
(3) 4- to 10-membered saturated heterocyclyloxy which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy,
(4) C1-6 alkyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,
(5) C3-7 cycloalkyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy,
(6) C1-6 alkylthio which may be substituted with 1-3 the same or different halogen atoms,
(7) 4- to 10-membered saturated heterocyclyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy,
(8) amino which may be substituted with 1-2 the same or different C1-6 alkyl which may be substituted with 1-3 the same or different halogen atoms,
(9) halogen atom, or
(10) hydroxy;
R2 is C1-6 alkyl (which may be substituted with 1-3 the same or different halogen atoms), C3-7 cycloalkyl, or amino (which may be substituted with 1-2 the same or different C1-6 alkyl);
Ring Q1 is
(1) C6-10 aryl which may be substituted with 1-5 the same or different substituents selected from the group consisting of
(a) halogen atom,
(b) cyano,
(c) C1-6 alkyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, C3-7 cycloalkyl, C1-6 alkoxy, and 4- to 7-membered saturated heterocyclyl,
(d) C1-6 alkylsulfonyl which may be substituted with 1-3 the same or different halogen atoms,
(e) C1-6 alkoxy which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, C3-7 cycloalkyl, C1-6 alkoxy, and 4- to 7-membered saturated heterocyclyl,
(f) C3-7 cycloalkyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy,
(g) C3-7 cycloalkoxy which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy,
(h) amino which may be substituted with 1-2 the same or different C1-6 alkyl which may be substituted with 1-3 the same or different halogen atoms,
(i) phenyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy, and
(j) 5- or 6-membered heteroaryl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy, or
(2) 5- to 10-membered heteroaryl which may be substituted with 1-4 the same or different substituents selected from the group consisting of (a)-(j) in the above (1) C6-10 aryl;
W1 is single bond, or C1-4 alkylene which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy;
Ring Q2 is C6-10 aromatic carbocyclyl, or 5- to 10-membered aromatic heterocyclyl;
n is 1, 2, 3, or 4;
R3 is, independently if there are plural R3,
(1) hydrogen atom,
(2) halogen atom,
(3) cyano,
(4) hydroxy,
(5) C1-6 alkyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,
(6) C1-6 alkoxy which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,
(7) C3-7 cycloalkyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy,
(8) C3-7 cycloalkoxy which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy, or
(9) amino which may be substituted with 1-2 the same or different C1-6 alkyl which may be substituted with 1-3 the same or different halogen atoms;
Q2-X1— is Q2-(single bond)-, Q2-(CH2)m—O—, Q2-(CH2)m—S—, Q2-(CH2)m—S(O)2—, Q2-(CH2)m—NRaS(O)2—, Q2-(CH2)m—S(O)2NRa—, Q2-(CH2)m—C(O)—, Q2-(CH2)m—NRa—, Q2-(CH2)m—NRaC(O)—, or Q2-(CH2)m—C(O)NRa—-, wherein Ra is hydrogen atom or C1-6 alkyl; m is 0, 1, or 2;
W2 is single bond, or C1-8 alkylene which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy; and
R4 is
(1) hydrogen atom,
(2) —ORb wherein Rb is hydrogen atom, C1-6 alkyl, C1-6 alkylcarbonyl, mono- or di-C1-6 alkyl-aminocarbonyl, or C1-6 alkylsulfonyl,
(3) —NRcRd wherein Rc is hydrogen atom or C1-6 alkyl which may be substituted with 1-3 the same or different halogen atoms; and Rd is hydrogen atom, C1-6 alkyl (which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, amino (which may be substituted with 1-2 the same or different C1-6 alkyl), and C1-6 alkoxy), C1-6 alkylcarbonyl (which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, amino (which may be substituted with 1-2 the same or different C1-6 alkyl), and C1-6 alkoxy), C1-6 alkoxycarbonyl, or C1-6 alkylsulfonyl,
(4) 4- to 10-membered saturated heterocyclyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of
(a) halogen atom,
(b) hydroxy,
(c) cyano,
(d) C1-6 alkyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,
(e) C1-6 alkoxy which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,
(f) C3-7 cycloalkyl,
(g) C1-6 alkylcarbonyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, amino (which may be substituted with 1-2 the same or different C1-6 alkyl), and C1-6 alkoxy,
(h) C1-6 alkoxycarbonyl,
(i) 4- to 7-membered saturated heterocyclyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy,
(j) phenyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy,
(k) 5- or 6-membered heteroaryl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy, and
(1) oxo, or
(5) 5- to 10-membered heteroaryl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy.

### Claim 3 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
R1 is C1-6 alkoxy (which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, C1-6 alkoxy, C3-7 cycloalkyl and 4- to 7-membered saturated heterocyclyl), 4- to 10-membered saturated heterocyclyloxy (which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, and C1-6 alkyl), Ci-6 alkyl (which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy), 4- to 10-membered saturated heterocyclyl (which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy), amino (which may be substituted with 1-2 the same or different C1-6 alkyl), halogen atom, or hydroxy.

### Claim 4 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
R1 is C1-6 alkoxy (which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy), or halogen atom.

### Claim 5 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R2 is C1-6 alkyl or amino.

### Claim 6 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
Ring Q1 is
(1) C6-10 aryl which may be substituted with 1-5 the same or different substituents selected from the group consisting of
(a) halogen atom,
(b) cyano,
(c) C1-6 alkyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, C1-6 alkoxy, and 4- to 7-membered saturated heterocyclyl,
(d) C1-6 alkylsulfonyl,
(e) C1-6 alkoxy which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, C1-6 alkoxy, and 4- to 7-membered saturated heterocyclyl, and
(f) amino which may be substituted with 1-2 the same or different C1-6 alkyl, or
(2) 5- to 10-membered heteroaryl which may be substituted with 1-4 the same or different substituents selected from the group consisting of (a)-(f) in the above (1) C6-10 aryl.

### Claim 7 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
Ring Q1 is
(1) phenyl which may be substituted with 1-5 the same or different substituents selected from the group consisting of
(a) halogen atom,
(b) cyano,
(c) C1-6 alkyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy, and
(d) C1-6 alkoxy which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,
(2) pyridyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of (a)-(d) in the above (1),
(3) pyrimidinyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of (a)-(d) in the above (1),
(4) pyridazinyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of (a)-(d) in the above (1),
(5) pyrazolyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of (a)-(d) in the above (1),
(6) furyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of (a)-(d) in the above (1), or
(7) isoxazolyl which may be substituted with 1-2 the same or different substituents selected from the group consisting of (a)-(d) in the above (1).

### Claim 8 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
Ring Q1 is
(1) pyridyl which may be substituted with 1-5 the same or different substituents selected from the group consisting of
(a) halogen atom,
(b) cyano,
(c) C1-6 alkyl which may be substituted with 1-3 the same or different halogen atoms, and
(d) C1-6 alkoxy which may be substituted with 1-3 the same or different halogen atoms, or
(2) pyrimidinyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of (a)-(d) in the above (1).

### Claim 9 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein W1 is methylene.

### Claim 10 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Ring Q2 is benzene ring group, or 5- or 6-membered aromatic heterocyclyl.

### Claim 11 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Ring Q2 is pyridine ring group, pyrazole ring group, isoxazole ring group, or benzene ring group.

### Claim 12 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen atom, halogen atom, cyano, hydroxy, C1-6 alkyl (which may be substituted with 1-3 the same or different halogen atoms), or C1-6 alkoxy (which may be substituted with 1-3 the same or different halogen atoms).

### Claim 13 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
Q2-X1— is Q2-(single bond)-, Q2-(CH2)m—O—, Q2-(CH2)m—C(O)—, Q2-(CH2)m—NRa—, or Q2-(CH2)—C(O)NRa—, wherein Ra is hydrogen atom or C1-6 alkyl; m is 0, 1, or 2.

### Claim 14 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X1 is single bond or —O—.

### Claim 15 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein W2 is single bond or C1-3 alkylene.

### Claim 16 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein W2 is single bond or methylene.

### Claim 17 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
R4 is
(1) hydrogen atom,
(2) —ORb wherein Rb is hydrogen atom, C1-6 alkyl, or C1-6 alkylsulfonyl,
(3) —NRcRd wherein Rc and Rd are independently hydrogen atom or C1-6 alkyl which may be substituted with 1-3 the same or different halogen atoms,
(4) 4- to 10-membered saturated heterocyclyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of
(a) halogen atom,
(b) hydroxy,
(c) cyano,
(d) C1-6 alkyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,
(e) C1-6 alkoxy which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,
(f) C3-7 cycloalkyl,
(g) C1-6 alkylcarbonyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, amino (which may be substituted with 1-2 the same or different C1-6 alkyl), and C1-6 alkoxy,
(h) C1-6 alkoxycarbonyl,
(i) 4- to 7-membered saturated heterocyclyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy, and
(j) oxo, or
(5) 5- to 10-membered heteroaryl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1i-6 alkyl, and C1-6 alkoxy.

### Claim 18 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
R4 is
(1) —NRcRd wherein Rc and Rd are independently hydrogen atom or C1-6 alkyl which may be substituted with 1-3 the same or different halogen atoms, or
(2) 4- to 10-membered saturated nitrogen-containing heterocyclyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of
(a) halogen atom,
(b) hydroxy,
(c) cyano,
(d) C1-6 alkyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,
(e) C1-6 alkoxy which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,
(f) C3-7 cycloalkyl,
(g) C1-6 alkylcarbonyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, amino (which may be substituted with 1-2 the same or different C1-6 alkyl), and C1-6 alkoxy, and
(h) 4- to 7-membered saturated heterocyclyl.

### Claim 19 (depends on 1)

The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein formula (1) is represented as formula (1a):
wherein
R11 is C1-6 alkoxy (which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, C1-6 alkoxy, C3-7 cycloalkyl and 4- to 7-membered saturated heterocyclyl), 4- to 10-membered saturated heterocyclyloxy (which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, and C1-6 alkyl), C1-6 alkyl (which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy), 4- to 10-membered saturated heterocyclyl (which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy), amino (which may be substituted with 1-2 the same or different C1-6 alkyl), halogen atom, or hydroxy;
R12 is C1-6 alkyl or amino;
Ring Q11 is
(1) C6-10 aryl which may be substituted with 1-5 the same or different substituents selected from the group consisting of
(a) halogen atom,
(b) cyano,
(c) C1-6 alkyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, C1-6 alkoxy, and 4- to 7-membered saturated heterocyclyl,
(d) C1-6 alkylsulfonyl,
(e) C1-6 alkoxy which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and 4- to 7-membered saturated heterocyclyl, and
(f) amino which may be substituted with 1-2 the same or different C1-6 alkyl, or
(2) 5- to 10-membered heteroaryl which may be substituted with 1-4 the same or different substituents selected from the group consisting of (a)-(f) in the above (1) C6-10 aryl;
Ring Q12 is benzene ring group, or 5- or 6-membered aromatic heterocyclyl;
R13 is hydrogen atom, halogen atom, hydroxy, C1-6 alkyl (which may be substituted with 1-3 the same or different halogen atoms), or C1-6 alkoxy (which may be substituted with 1-3 the same or different halogen atoms);
Q12-X11— is Q12-(single bond)-, Q12-(CH2)m—O—, Q12-(CH2)m—C(O)—, Q12-(CH2)m—NRa—, or Q12-(CH2)m—C(O)NRa—, wherein Ra is hydrogen atom or C1-6 alkyl; m is 0, 1, or 2;
W12 is single bond or C1-3 alkylene; and
R14 is
(1) hydrogen atom,
(2) —ORb wherein Rb is hydrogen atom, C1-6 alkyl, or C1-6 alkylsulfonyl,
(3) —NRcRd wherein Rc and Rd are independently hydrogen atom, or C1-6 alkyl which may be substituted with 1-3 the same or different halogen atoms,
(4) 4- to 10-membered saturated heterocyclyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of
(a) halogen atom,
(b) hydroxy,
(d) C1-6 alkyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,
(e) C1-6 alkoxy which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy,
(f) C3-7 cycloalkyl,
(g) C1-6 alkylcarbonyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, amino (which may be substituted with 1-2 the same or different C1-6 alkyl), and C1-6 alkoxy,
(h) C1-6 alkoxycarbonyl,
(i) 4- to 7-membered saturated heterocyclyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy, and
(j) oxo, or
(5) 5- to 10-membered heteroaryl which may be substituted with 1-4 the same or different substituents selected from the group consisting of halogen atom, C1-6 alkyl, and C1-6 alkoxy.

### Claim 20 (depends on 19)

The compound of claim 19 or a pharmaceutically acceptable salt thereof, wherein R12 is C1-4 alkyl.

### Claim 21 (depends on 19)

The compound of claim 19 or a pharmaceutically acceptable salt thereof, wherein R13 is hydrogen atom or halogen atom.

### Claim 22 (depends on 19)

The compound of claim 19 or a pharmaceutically acceptable salt thereof, wherein
Ring Q11 is
(1) pyridyl which may be substituted with 1-4 the same or different substituents selected from the group consisting of
(a) halogen atom,
(b) cyano,
(c) C1-6 alkyl which may be substituted with 1-3 the same or different halogen atoms, and
(d) C1-6 alkoxy which may be substituted with 1-3 the same or different halogen atoms, or
(2) pyrimidinyl which may be substituted with 1-3 the same or different substituents selected from the group consisting of (a)-(d) in the above (1).

### Claim 23 (depends on 19)

The compound of claim 19 or a pharmaceutically acceptable salt thereof, wherein Ring Q11 is 5-fluoropyridin-3-yl, 5-cyanopyridin-3-yl, pyridin-3-yl, or pyrimidinyl.

### Claim 24 (depends on 19)

The compound of claim 19 or a pharmaceutically acceptable salt thereof, wherein Ring Q12 is pyridine ring group, pyrazole ring group, isoxazole ring group, or benzene ring group.

### Claim 25 (depends on 19)

The compound of claim 19 or a pharmaceutically acceptable salt thereof, wherein
R14 is the following formula (2), (3), (4), (5), (6), (7), (8), (9), (10), (11), (12), (13), (14), (15), or (16):
wherein
R15 is halogen, hydroxy, C1-6 alkyl (which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy), C3-7 cycloalkyl, C1-6 alkylcarbonyl (which may be substituted with one amino which may be substituted with 1-2 the same or different C1-6 alkyl), or 4- to 7-membered saturated heterocyclyl.

### Claim 26 (depends on 19)

The compound of claim 19 or a pharmaceutically acceptable salt thereof, wherein
R14 is the following formula (2), (3), (4), (5), (6), (7), (8), (9), or (10):
wherein
R15 is halogen, hydroxy, C1-6 alkyl (which may be substituted with 1-3 the same or different substituents selected from the group consisting of halogen atom, hydroxy, and C1-6 alkoxy), C3-7 cycloalkyl, C1-6 alkylcarbonyl (which may be substituted with one amino which may be substituted with 1-2 the same or different C1-6 alkyl), or 4- to 7-membered saturated heterocyclyl.

### Claim 27 (depends on 1)

The compound of claim 1 which is selected from the following compounds, or a pharmaceutically acceptable salt thereof:
9-({6-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridin-3-yl}methyl)-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-({6-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridin-3-yl}methyl)-2-ethoxy-8-(5-fluoropyridin-3-yl)-6-methyl-9H-purine,
8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9-(4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-9H-purine,
2-ethoxy-8-(5-fluoropyridin-3-yl)-6-methyl-9-(4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-9H-purine,
2-ethoxy-8-(5-fluoropyridin-3-yl)-6-methyl-9-(4-{[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-9H-purine,
2-ethoxy-9-(4-{[(1S,4S)-5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-8-(5-fluoropyridin-3-yl)-6-methyl-9H-purine,
9-(4-{[(1S,4S)-5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9-(4-{[(1S,4S)-5-propyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-9H-purine,
9-{4-[(5R)-1,4-diazabicyclo[3.2.1]oct-4-ylmethyl]benzyl}-2-ethoxy-8-(5-fluoropyridin-3-yl)-6-methyl-9H-purine,
9-{4-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]benzyl}-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
2-ethoxy-8-(5-fluoropyridin-3-yl)-6-methyl-9-{4-[(4-methylpiperazine-1-yl)methyl]benzyl}-9H-purine,
9-[4-(1-azabicyclo[2.2.2]oct-3-yl)-2-methoxybenzyl]-2-ethoxy-8-(5-fluoropyridin-3-yl)-6-methyl-9H-purine,
2-(1-azabicyclo[2.2.2]oct-3-yl)-5-{[2-ethoxy-8-(5-fluoropyridin-3-yl)-6-methyl-9H-purin-9-yl]methyl}benzonitrile,
9-{[-(1-azabicyclo[2.2.2]oct-3-ylmethyl)-1H-pyrazol-4-yl]methyl}-2-ethoxy-8-(5-fluoropyridin-3 -yl)-6-methyl-9H-purine,
2-(1-azabicyclo[2.2.2]oct-3-yl)-5-{[84-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purin-9-yl]methyl}benzonitrile,
9-{2-fluoro-4-[(1-methylpiperidin-4-yl)methyl]benzyl}-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-{2-fluoro-4-[(1-methylazetidin-3-yl)methoxy]benzyl}-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
5-{9-[4-(1-ethylpiperidin-4-yl)-2-fluorobenzyl]-2-methoxy-6-methyl-9H-purin-8-yl}pyridine-3-carbonitrile,
9-[2-fluoro-4-(1-methylpyrrolidin-3-yl)benzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-[4-(1-ethylpyrrolidin-3-yl)-2-fluorobenzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-[2-fluoro-4-(1-methylpiperidin-4-yl)benzyl]-2-methoxy-6-methyl-8-(pyridin-3-yl)-9H-purine,
9-[4-(1-ethylpiperidin-4-yl)-2-fluorobenzyl]-2-methoxy-6-methyl-8-(pyridin-3-yl)-9H-purine,
9-(2-fluoro-4-{[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}benzyl)-2-methoxy-6-methyl-8-(pyridin-3-yl)-9H-purine,
9-{4-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]-2-fluorobenzyl}-2-methoxy-6-methyl-8-(pyrimidin-5-yl)-9H-purine,
3-{9-[4-(1-azabicyclo[2.2.2]oct-3-yl)-2-fluorobenzyl]-2-methoxy-6-methyl-9H-purin-8-yl}benzonitrile,
9-[4-(1-azabicyclo[2.2.2]oct-3-yl)-3-fluorobenzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-[3-(1-azabicyclo[2.2.2]oct-3-yl)benzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-{[6-(1-azabicyclo[2.2.2]oct-3-yl)-2-methylpyridin-3-yl]methyl}-2-ethoxy-8-(5-fluoropyridin-3-yl)-6-methyl-9H-purine,
9-{4-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]-2-fluorobenzyl}-2-methoxy-6-methyl-8-(pyridin-3-yl)-9H-purine,
9-{2-fluoro-4-[(1-methylpiperidin-4-yl)oxy]benzyl}-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-(2-fluoro-4-{[(3S)-1-methylpyrrolidin-3-yl]oxy}benzyl)-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-(2-fluoro-4-{[(3R)-1-methylpyrrolidin-3-yl]oxy}benzyl)-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-{2-fluoro-4-[(1-methylazetidin-3-yl)oxy]benzyl}-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
1-(3-fluoro-4-{[8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purin-9-yl]methyl}phenyl)-N,N-dimethylmethanamine,
9-[4-(azetidin-1-ylmethyl)-2-fluorobenzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-(2-fluoro-4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-[2-fluoro-4-(1-methylpiperidin-4-yl)benzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-[4-(1-ethylpiperidin-4-yl)-2-fluorobenzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-(2-fluoro-4-{[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}benzyl)-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-(2-fluoro-4-{[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}benzyl)-2-methoxy-6-methyl-8-(pyrimidin-5-yl)-9H-purine,
5-[9-(2-fluoro-4-{[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}benzyl)-2-methoxy-6-methyl-9H-purin-8-yl]pyridine-3-carbonitrile,
5-[9-(4-{[(3-endo)-8-ethyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}-2-fluorobenzyl)-2-methoxy-6-methyl-9H-purin-8-yl]pyridine-3-carbonitrile,
9-[4-(1-azabicyclo[2.2.2]oct-3-yl)-2-fluorobenzyl]-2-methoxy-6-methyl-8-(pyridin-3-yl)-9H-purine,
9-[4-(1-azabicyclo[2.2.2]oct-3-yl)-2-fluorobenzyl]-2-methoxy-6-methyl-8-(4-methylpyridin-3-yl)-9H-purine,
9-[4-(1-azabicyclo[2.2.2]oct-3-yl)-2-fluorobenzyl]-2-methoxy-6-methyl-8-(5-methylpyridin-3-yl)-9H-purine,
5-[9-(2-fluoro-4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-2-methoxy-6-methyl-9H-purin-8-yl]pyridine-3-carbonitrile,
5-[9-(4-{[(1S,4S)-5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}-2-fluorobenzyl)-2-methoxy-6-methyl-9H-purin-8-yl]pyridine-3-carbonitrile,
9-(2-fluoro-4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-2-methoxy-6-methyl-8-(pyridin-3-yl)-9H-purine,
5-[2-ethoxy-9-(2-fluoro-4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-6-methyl-9H-purin-8-yl]pyridine-3-carbonitrile,
2-ethoxy-9-(2-fluoro-4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-6-methyl-8-(pyrimidin-5-yl)-9H-purine,
2-ethoxy-9-(2-fluoro-4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-8-(5-fluoropyridin-3-yl)-6-methyl-9H-purine,
5-(9-{4-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]-2-fluorobenzyl}-2-methoxy-6-methyl-9H-purin-8-yl)pyridine-3-carbonitrile,
9-{[6-(1-azabicyclo[2.2.2]oct-3-yl)pyridin-3-yl]methyl}-2-ethoxy-8-(5-fluoropyridin-3-yl)-6-methyl-9H-purine,
9-[4-(1-azabicyclo[2.2.2]oct-3-yl)-2-fluorobenzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
5-{9-[4-(1-azabicyclo[2.2.2]oct-3-yl)-2-fluorobenzyl]-2-methoxy-6-methyl-9H-purin-8-yl}pyridine-3-carbonitrile,
9-{4-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]-2-fluorobenzyl}-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]-2-fluorobenzyl}-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-(2-fluoro-4-{[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}benzyl)-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine, and
9-[5-(1-azabicyclo[2.2.2]oct-3-yl)-2-fluorobenzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine.

### Claim 28 (depends on 1)

The compound of claim 1 which is selected from the following compounds, or a pharmaceutically acceptable salt thereof:
1-(3-fluoro-4-{[8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purin-9-yl]methyl}phenyl)-N,N-dimethylmethanamine,
9-[4-(azetidin-1-ylmethyl)-2-fluorobenzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-(2-fluoro-4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-[2-fluoro-4-(1-methylpiperidin-4-yl)benzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-[4-(1-ethylpiperidin-4-yl)-2-fluorobenzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-(2-fluoro-4-{[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}benzyl)-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-(2-fluoro-4-{[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}benzyl)-2-methoxy-6-methyl-8-(pyrimidin-5-yl)-9H-purine,
5-[9-(2-fluoro-4-{[(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}benzyl)-2-methoxy-6-methyl-9H-purin-8-yl]pyridine-3-carbonitrile,
5-[9-(4-{[(3-endo)-8-ethyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}-2-fluorobenzyl)-2-methoxy-6-methyl-9H-purin-8-yl]pyridine-3-carbonitrile,
9-[4-(1-azabicyclo[2.2.2]oct-3-yl)-2-fluorobenzyl]-2-methoxy-6-methyl-8-(pyridin-3-yl)-9H-purine,
9-[4-(1-azabicyclo[2.2.2]oct-3-yl)-2-fluorobenzyl]-2-methoxy-6-methyl-8-(4-methylpyridin-3-yl)-9H-purine,
9-[4-(1-azabicyclo[2.2.2]oct-3-yl)-2-fluorobenzyl]-2-methoxy-6-methyl-8-(5-methylpyridin-3-yl)-9H-purine,
5-[9-(2-fluoro-4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-2-methoxy-6-methyl-9H-purin-8-yl]pyridine-3-carbonitrile,
5-[9-(4-{[(1S,4S)-5-ethyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}-2-fluorobenzyl)-2-methoxy-6-methyl-9H-purin-8-yl]pyridine-3-carbonitrile,
9-(2-fluoro-4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-2-methoxy-6-methyl-8-(pyridin-3-yl)-9H-purine,
5-[2-ethoxy-9-(2-fluoro-4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-6-methyl-9H-purin-8-yl]pyridine-3-carbonitrile,
2-ethoxy-9-(2-fluoro-4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-6-methyl-8-(pyrimidin-5-yl)-9H-purine,
2-ethoxy-9-(2-fluoro-4-{[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]hept-2-yl]methyl}benzyl)-8-(5-fluoropyridin-3-yl)-6-methyl-9H-purine,
5-(9-{4-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]-2-fluorobenzyl}-2-methoxy-6-methyl-9H-purin-8-yl)pyridine-3-carbonitrile,
9-{[6-(1-azabicyclo[2.2.2]oct-3-yl)pyridin-3-yl]methyl}-2-ethoxy-8-(5-fluoropyridin-3-yl)-6-methyl-9H-purine,
9-[4-(1-azabicyclo[2.2.2]oct-3-yl)-2-fluorobenzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
5-{9-[4-(1-azabicyclo[2.2.2]oct-3-yl)-2-fluorobenzyl]-2-methoxy-6-methyl-9H-purin-8-yl}pyridine-3-carbonitrile,
Example 412: 9-{4-[(3S)-1-azabicyclo[2.2.2]oct-3-yloxy]-2-fluorobenzyl}-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-{4-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]-2-fluorobenzyl}-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine,
9-(2-fluoro-4-{[(3-exo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl]oxy}benzyl)-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine, and
9-[5-(1-azabicyclo[2.2.2]oct-3-yl)-2-fluorobenzyl]-8-(5-fluoropyridin-3-yl)-2-methoxy-6-methyl-9H-purine.

### Claim 29 (depends on 1)

A medicament comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 30 (depends on 1)

A medicament for treating autoimmune disease, comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 31 (depends on 1)

An TLR7 inhibitor comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 32 (depends on 1)

A medicament for treating systemic lupus erythematosus, lupus nephritis, Sjogren's syndrome, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, polymyositis, dermatomyositis, Behcet's disease, multiple sclerosis, or pemphigus, comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim 33 (depends on 1)

A medicament comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof in combination with at least one agent selected from steroid drugs, immunosuppressive drugs, agents against B cells, TLR inhibitors, and other agents for treating autoimmune disease.

### Claim 34 (depends on 1)

Use of the compound of claim 1 or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating systemic lupus erythematosus, lupus nephritis, Sjogren's syndrome, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, polymyositis, dermatomyositis, Behcet's disease, multiple sclerosis, or pemphigus.

### Claim 35 (depends on 1)

A method for treating systemic lupus erythematosus, lupus nephritis, Sjogren's syndrome, idiopathic thrombocytopenic purpura, psoriasis, rheumatoid arthritis, polymyositis, dermatomyositis, Behcet's disease, multiple sclerosis, or pemphigus, comprising administering a therapeutically effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof to a mammal.